RecruitingNCT05392881
Interstitial Lung Disease Research Unit Biobank
University of Kansas Medical Center Interstitial Lung Disease Research Unit (ILDRU) Biobank
Sponsor
University of Kansas Medical Center
Enrollment
1,000 participants
Start Date
Aug 9, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
Establish a interstitial lung disease (ILD) registry and biorepository to lead towards a further understanding of the disease.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- The participant is a patient at TUKHS or has agreed to participate in a study approved by the KUMC Human Research Protection Program (HRPP)
- The participant is being followed for the presence of autoimmune disease, ILD or other rare lung diseases at TUKHS.
- The participant is ≥ 18 years of age.
- The participant has signed an approved consent for this study (living patients only)
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05392881
Related Trials
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622372 locations
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
NCT072302884 locations
Role of Genetic Factors in the Development of Lung Disease
NCT000015322 locations
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT0717938049 locations
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535150 locations